Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Robert Z. Orlowski
A Randomized Phase 2 Trial of a Preparative Regimen of Bortezomib, High-Dose Melphalan, Arsenic Trioxide, and Ascorbic Acid
Cancer
Cancer Research
Oncology
Final Overall Survival Results of a Randomized Trial Comparing Bortezomib Plus Pegylated Liposomal Doxorubicin With Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma
Cancer
Cancer Research
Oncology
Disease and Outcome Disparities in Multiple Myeloma: Exploring the Role of Race/Ethnicity in the Cooperative Group Clinical Trials
Blood Cancer Journal
Oncology
Hematology
The Nuclear Factor (Erythroid-Derived 2)-Like 2 and Proteasome Maturation Protein Axis Mediate Bortezomib Resistance in Multiple Myeloma
Journal of Biological Chemistry
Biochemistry
Cell Biology
Molecular Biology
Evidence of a Role for Activation of WNT/Β-Catenin Signaling in the Resistance of Plasma Cells to Lenalidomide
Journal of Biological Chemistry
Biochemistry
Cell Biology
Molecular Biology
Pembrolizumab Combined With Lenalidomide and Low‐dose Dexamethasone for Relapsed or Refractory Multiple Myeloma: Phase I KEYNOTE ‐023 Study
British Journal of Haematology
Hematology
Truncated Protein Tyrosine Phosphatase Receptor Type O Suppresses AKT Signaling Through IQ Motif Containing GTPase Activating Protein 1 and Confers Sensitivity to Bortezomib in Multiple Myeloma
Oncotarget
Oncology
Biological Effects of the Pim Kinase Inhibitor, SGI-1776, in Multiple Myeloma
Clinical Lymphoma, Myeloma and Leukemia
Cancer Research
Oncology
Hematology
Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation
Clinical Lymphoma, Myeloma and Leukemia
Cancer Research
Oncology
Hematology
Curability of Multiple Myeloma.
Blood
Biochemistry
Immunology
Cell Biology
Hematology
